Industry Symposia

Novartis Breakfast Symposium

Date: Monday 28th August 

Time: 7.00am to 8.00am (breakfast served from 6:45am)

Title: In Acromegaly, CONTROL IS CRITICAL

Content: Uncontrolled biochemical levels in acromegaly may increase mortality. 45% of patients treated with first generation SSAs remain uncontrolled. Next generation treatment options are now available that help achieve biochemical control and tumour volume shrinkage.         

Topic 1: Uncontrolled biochemical control in Acromegaly and associated co-morbidities
Topic 2: Signifor LAR (Pasreotide) in patients with inadequately controlled Acromegaly

Speakers: Professor Mark McLean and Dr Carmela Caputo

Chair: TBC

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

This session is supported and organised byNovartis large  

 

Eisai Breakfast Symposium

Date: Monday 28th August

Time: 7.00am to 8.00am (breakfast served from 6:45am)

Title: Navigating the new landscape of managing radioiodine refractory differentiated thyroid Cancer

Content: The 10-year survival rate among patients with differentiated thyroid cancer who have become refractory to radioactive iodine therapy is 10% from the time of detection of metastasis. Although treatment options have historically been limited for these patients, systemic treatment through the use of Tyrosine Kinase Inhibitors (TKIs) are now accepted as the standard of care for metastatic, refractory, progressive patients not amenable to local therapy. This symposium will bring together four Australian experts in the management of refractory thyroid cancer to discuss the new treatment landscape for radioiodine refractory differentiated thyroid cancer and the use of TKIs. Specifically the expert panel will share their clinical experience in the use of Lenvima (Lenvatinib) including factors which should be considered when determining who may be appropriate for systemic treatment, the optimal time for treatment initiation and how to manage adverse events and dose modifications through a case-based discussion.

Speakers: Professor Bruce Robinson, Associate Professor Roderick Clifton-Bligh, Associate Professor Ben Solomon, Dr David Pattison.
Chair: Professor Bruce Robinson

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

 This session is supported and organised byEisailogo

 

Pfizer Breakfast Symposium

Date: Tuesday 29th August 

Time: 7.00am to 8.00am (breakfast served from 6:45am)

Title: Somavert®(pegvisomant) – the role of a growth hormone receptor antagonist (GHRA) in uncontrolled acromegaly

Content:
- A clinical need for pegvisomant: a case presentation
- Treatment of uncontrolled acromegaly with pegvisomant – indication, efficacy, safety, genetic considerations
- Questions from the audience

Topic 1: Clinical need for growth hormone receptor antagonist (GHRA) in Australia
Topic 2: Treatment of uncontrolled acromegaly with Somavert® (pegvisomant)

Speakers: Professor Ken Ho and Professor Marta Korbonits
Chair: Prof. Ken Ho

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

 This session is supported and organised byPfizer Endocrine Care1

 

 


Our Sponsors